Skip to main navigation

Skip to content

Side Menu

About Us
Our Platform
Our Products
Our Programs
Patients and Physicians
Inside Seres
Open Positions
Investors and News
Contact Us

Press Releases

Seres' news, events and other information can be found throughout the pages below.

Investor Relations

Stock Information
News and Events
- Press Releases
- Events & Presentations
Financial Information
- SEC Filings
- Annual Reports
Corporate Governance
Shareholder Services

Press Releases

Keyword Search

Year

Aug 06, 2024

Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science

Aug 06, 2024

Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024

Jun 07, 2024

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 06, 2024

Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science

May 08, 2024

Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 06, 2024

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 06, 2024

Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024

Apr 09, 2024

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Mar 28, 2024

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 19, 2024

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

Shareholder Tools

RSS Feeds
E-mail Alerts
Print

© 2024 Seres Therapeutics.

Footer Left Menu

Privacy Policy
Terms of Use

Follow us on Linkedin
Follow us on Twitter
Follow us on Facebook